People reporting device-related adverse events to the US Food and Drug Administration can now include more information about the affected patients, the agency announced today.
FDA Collects More Demographics Data In MAUDE
The adverse event database will now collect patient age, weight, ethnicity and race, which aligns with recent FDA efforts to better track information on how medical products may affect people from different demographic groups.
More from Regulation
• By
Manufacturers of medical products would be foolish to think that recent upheavals at the US FDA will result in a lack of inspections in the coming years. A panel of experts discussed the current state of inspections during a webinar hosted by the Food and Drug Law Institute.
• By
The intricate assembly of medical devices, often involving over 1,000 globally sourced components, faces severe disruption due to new US tariffs. These barriers could halt production and devastate small and medium-sized enterprises (SMEs), MedTech Europe’s CEO, Oliver Bisazza, warns in an interview with Medtech Insight.
• By
A New South Korean law, the Digital Medical Products Act, enhances regulation for digital health products. Medical devices in the country are categorized both by risk and by similarity to already authorized devices. The approval process may stretch to 515 days for new manufacturers.
• By
Its move comes as the Swiss recognize the need to ensure adequate supplies on medical devices in its country.
More from Policy & Regulation
• By
A New South Korean law, the Digital Medical Products Act, enhances regulation for digital health products. Medical devices in the country are categorized both by risk and by similarity to already authorized devices. The approval process may stretch to 515 days for new manufacturers.
• By
Its move comes as the Swiss recognize the need to ensure adequate supplies on medical devices in its country.
• By
Recognizing that the evidence it receives in applications for health technology assessments will increasingly be informed by artificial intelligence, the CDA-AMC has clarified its expectations for companies that use AI methods in the generation and/or reporting of evidence.